Equities research analysts predict that Heat Biologics Inc (NASDAQ:HTBX) will report $920,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Heat Biologics’ earnings, with the highest sales estimate coming in at $1.10 million and the lowest estimate coming in at $740,000.00. Heat Biologics posted sales of $2.06 million in the same quarter last year, which suggests a negative year over year growth rate of 55.3%. The business is scheduled to announce its next quarterly earnings results on Thursday, March 26th.

According to Zacks, analysts expect that Heat Biologics will report full year sales of $2.50 million for the current year, with estimates ranging from $2.10 million to $2.89 million. For the next fiscal year, analysts expect that the firm will report sales of $2.80 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Heat Biologics.

Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Friday, November 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.91 million. Heat Biologics had a negative net margin of 695.62% and a negative return on equity of 88.07%.

Separately, ValuEngine raised shares of Heat Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, December 4th.

HTBX remained flat at $$0.33 during midday trading on Friday. 2,460,920 shares of the company’s stock traded hands, compared to its average volume of 1,293,943. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.29 and a quick ratio of 3.29. The stock has a market cap of $12.62 million, a P/E ratio of -0.37 and a beta of 1.78. Heat Biologics has a fifty-two week low of $0.29 and a fifty-two week high of $1.80. The stock’s 50-day moving average price is $0.46 and its 200 day moving average price is $0.52.

An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. raised its stake in shares of Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,327,660 shares of the biopharmaceutical company’s stock after purchasing an additional 84,400 shares during the period. Vanguard Group Inc. owned 3.90% of Heat Biologics worth $909,000 at the end of the most recent quarter. 4.83% of the stock is owned by institutional investors and hedge funds.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Read More: Are sell-side analysts objective?

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.